Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 7/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | HPGDS | O60760 | 4/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.54 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958373 | 1.00 | HSD17B1 (0.65) | HSD17B1HSD17B2CYP3A4CYP2C9PARP1 | |
| SCHEMBL21295488 | 0.89 | PARP1 (0.58) | HSD17B1HSD17B2CYP3A4CYP2C9PARP1 | |
| SCHEMBL1147444 | 0.86 | PARP1 (0.77) | HSD17B1HSD17B2CYP3A4CYP2C9PARP1 | |
| SCHEMBL22367342 | 0.85 | MKNK1 (0.64) | CYP3A4PARP1MKNK1MKNK2ERN1 | |
| SCHEMBL4677929 | 0.84 | HSD17B1 (0.71) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL2589651 | 0.84 | ERN1 (0.60) | CYP3A4PARP1MKNK1MKNK2ERN1 | |
| Urea SCHEMBL28406941 | 0.83 | HSD17B1 (0.68) | HSD17B1HSD17B2CYP3A4CYP2C9PARP1 | |
| SCHEMBL29876804 | 0.82 | EGFR (0.72) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL323567 | 0.82 | EGFR (0.72) | HSD17B1HSD17B2CYP3A4CYP2C9ESR1 | |
| SCHEMBL27373843 | 0.82 | HSD17B1 (0.60) | HSD17B1HSD17B2CYP3A4CYP2C9PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3865472-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2024-06-12 | — | — | EP | disclosed |
| EP-3865472-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA Therapeutics Limited (IE) | 2021-08-18 | — | — | EP | disclosed |
| US-10966994-B2 | Thromboxane receptor antagonists | ATXA THERAPEUTICS LIMITED (IE) | 2021-04-06 | — | — | US | disclosed |
| US-10966994-B2 | Thromboxane receptor antagonists | ATXA THERAPEUTICS LIMITED (IE) | 2021-04-06 | — | — | US | disclosed |
| EP-3310756-B1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LTD (IE) | 2020-12-09 | — | — | EP | disclosed |
| US-20190336513-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2019-11-07 | — | — | US | disclosed |
| US-10357504-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2019-07-23 | — | — | US | disclosed |
| US-10357504-B2 | Thromboxane receptor antagonists | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2019-07-23 | — | — | US | disclosed |
| US-20180179152-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2018-06-28 | — | — | US | disclosed |
| US-20180179152-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | ATXA THERAPEUTICS LIMITED (IE) | 2018-06-28 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-2054383-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HSD17B1 2970/4885HSD17B2 2553/4885CYP3A4 1734/4885 |
| US-10966994-B2 | Thromboxane receptor antagonists | TBXA2R, TBXAS1, PTGIR | HSD17B1 2031/4885HSD17B2 1597/4885CYP3A4 1009/4885 |
| US-20190336513-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
| US-20180179152-A1 | THROMBOXANE RECEPTOR ANTAGONISTS | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | HSD17B1 1414/4885HSD17B2 895/4885CYP3A4 3961/4885 |
| US-10357504-B2 | Thromboxane receptor antagonists | TBXA2R, PTGER2, PTGER1 | HSD17B1 1247/4885HSD17B2 820/4885CYP3A4 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.